CRDL logo

CRDL
Cardiol Therapeutics Inc - Ordinary Shares - Class A

5,664
Mkt Cap
$147.67M
Volume
578,846.00
52W High
$1.71
52W Low
$0.88
PE Ratio
-4.72
CRDL Fundamentals
Price
$1.32
Prev Close
$1.30
Open
$1.33
50D MA
$1.24
Beta
1.22
Avg. Volume
761,343.32
EPS (Annual)
-$0.2782
P/B
10.15
Rev/Employee
$0.00
$67.60
Loading...
Loading...
News
all
press releases
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address...
PR Newswire·11d ago
News Placeholder
Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year High - Here's Why
Cardiol Therapeutics (TSE:CRDL) Reaches New 52-Week High - Should You Buy...
MarketBeat·18d ago
News Placeholder
Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9% - Here's What Happened
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 7.9% - Should You Buy...
MarketBeat·22d ago
News Placeholder
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes could improve outcomes in conditions that currently have limited or no...
MarketBeat·24d ago
News Placeholder
Research Analysts Set Expectations for CRDL Q3 Earnings
Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at Brookline Capital Markets reduced their Q3 2026 EPS estimates for shares of Cardiol Therapeutics in a research report...
MarketBeat·1mo ago
News Placeholder
What is HC Wainwright's Forecast for CRDL Q1 Earnings?
Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research...
MarketBeat·1mo ago
News Placeholder
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group
Canaccord Genuity Group reaffirmed a "buy" rating and issued a $8.00 price target on shares of Cardiol Therapeutics in a report on Monday...
MarketBeat·1mo ago
News Placeholder
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Cardiol Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·1mo ago
News Placeholder
What is HC Wainwright's Estimate for CRDL FY2028 Earnings?
Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Research analysts at HC Wainwright boosted their FY2028 earnings per share estimates for Cardiol Therapeutics in a report issued on Thursday...
MarketBeat·1mo ago
<
1
2
...
>

Latest CRDL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.